Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): A randomised controlled trial

The Lancet Oncology

Volumn 15, Issue 8, 2014, Pages 809-818

  Vora, Ajay ^a   Goulden, Nick ^b   Mitchell, Chris ^c   Hancock, Jeremy ^d   Hough, Rachael ^e   Rowntree, Clare ^f   Moorman, Anthony V ^g   Wade, Rachel ^h  

^a SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d NORTH BRISTOL NHS TRUST   (United Kingdom)

^e UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^f UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^g NEWCASTLE UNIVERSITY   (United Kingdom)

^h UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; MERCAPTOPURINE; METHOTREXATE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; ASPARAGINASE HYPERSENSITIVITY; AVASCULAR NECROSIS; BLEEDING; BRAIN DISEASE; CANCER SURVIVAL; CHILD; CLINICAL PROTOCOL; CONSTIPATION; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; EVENT FREE SURVIVAL; FEMALE; HUMAN; HYPERSENSITIVITY; INFECTION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MOOD DISORDER; MUCOSA INFLAMMATION; NEUROPATHY; OVERALL SURVIVAL; PANCREATITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; STOMATITIS; THROMBOSIS; TREATMENT RESPONSE; VOMITING; YOUNG ADULT;

6-MERCAPTOPURINE; ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; CONSOLIDATION CHEMOTHERAPY; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG HYPERSENSITIVITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; MALE; METHOTREXATE; MUCOSITIS; NEOPLASM, RESIDUAL; PANCREATITIS; POLYETHYLENE GLYCOLS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REMISSION INDUCTION; RISK ASSESSMENT; STOMATITIS; SURVIVAL RATE; VINCRISTINE;

EID: 84903541143     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70243-8     Document Type: Article

References (23)

1. Cave H, van der Werff ten Bosch, Suciu S, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group. N Engl J Med 1998, 339:591-598.
2. van Dongen JJ, Seriu T, Panzer-Grumayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998, 352:1731-1738.
3. Coustan-Smith E, Behm FG, Sanchez J, et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 1998, 351:550-554.
4. Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010, 115:3206-3214.
5. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009, 360:2730-2741.
6. Yamaji K, Okamoto T, Yokota S, et al. Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group. Pediatr Blood Cancer 2010, 55:1287-1295.
7. Vora A, Goulden N, Wade R, et al. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol 2013, 14:199-209.
8. Szczepanski T, van der Velden VH, van Dongen JJ Classification systems for acute and chronic leukaemias. Best Pract Res Clin Haematol 2003, 16:561-582.
9. Biondi A, Schrappe M, Di Lorenzo P, et al. Efficacy and safety of imatinib on top of BFM-like chemotherapy in pediatric patients with Ph+/BCR-ABL+ acute lymphoblastic leukemia (Ph+ALL). The EsPhALL study. Blood 2011, 118:873.
10. Fielding AK, Rowe JM, Buck G, et al. UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood 2014, 123:843-850.
11. Bruggemann M, Schrauder A, Raff T, et al. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia 2010, 24:521-535.
12. Flohr T, Schrauder A, Cazzaniga G, et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 2008, 22:771-782.
13. Moorman AV, Ensor HM, Richards SM, et al. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol 2010, 11:429-438.
14. Mitchell C, Payne J, Wade R, et al. The impact of risk stratification by early bone-marrow response in childhood lymphoblastic leukaemia: results from the United Kingdom Medical Research Council trial ALL97 and ALL97/99. Br J Haematol 2009, 146:424-436.
15. Altman DG Practical statistics for medical research 1991, Chapman and Hall, London.
16. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992, 339:71-85. Early Breast Cancer Trialists' Collaborative Group.
17. Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 1998, 338:1663-1671.
18. Gaynon PS, Desai AA, Bostrom BC, et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. Cancer 1997, 80:1717-1726.
19. Seibel NL, Steinherz PG, Sather HN, et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2008, 111:2548-2555.
20. Lee-Sherick AB, Linger RM, Gore L, Keating AK, Graham DK Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development. Br J Haematol 2010, 151:295-311.
21. Mussai F, Campana D, Bhojwani D, et al. Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia. Br J Haematol 2010, 150:352-358.
22. Cario G, Schrauder A, Moericke A, Bourquin JP, Schrappe M, Stanulla M. Early diagnosis and molecular-based treatment of very highly resistant acute lymphoblastic leukemia in childhood. 50th ASH Annual Meeting and Exposition; San Francisco, CA; Dec 6-9, 2008. Abstract 754.
23. Izraeli S Application of genomics for risk stratification of childhood acute lymphoblastic leukaemia: from bench to bedside?. Br J Haematol 2010, 151:119-131.